tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Jul 31;10(8):1226.
doi: 10.3390/vaccines10081226.
Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin
Amal Hasan[SUP] 1 [/SUP], Hossein Arefanian[SUP] 1 [/SUP], Arshad Mohamed Channanath[SUP] 2 [/SUP], Irina AlKhairi[SUP] 3 [/SUP], Preethi Cherian[SUP] 3 [/SUP], Sriraman Devarajan[SUP] 4 [/SUP], Thangavel Alphonse Thanaraj[SUP] 2 [/SUP], Mohamed Abu-Farha[SUP] 4 [/SUP], Jehad Abubaker[SUP] 3 [/SUP], Fahd Al-Mulla[SUP] 2 [/SUP]
Affiliations
Abstract
Background: Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of thrombosis and thromboembolism. Exposure to COVID-19 vaccines is also associated with immune thrombotic thrombocytopenia, ischemic stroke, intracerebral haemorrhage, and cerebral venous thrombosis, and it is linked with systemic activation of coagulation.
Methods: We assess the circulating levels of coagulation factors (factors XI, XII, XIII, and prothrombin) and antithrombin in individuals who completed two doses of either ChAdOx1-S or BNT162b2 COVID-19 vaccine, within the timeframe of two months, who had no previous history of COVID-19.
Results: Elevated levels of factors XI, XII, XIII, prothrombin, and antithrombin were seen compared to unvaccinated controls. Levels of coagulation factors, antithrombin, and prothrombin to antithrombin ratio were higher with BNT162b2 compared to ChAdOx1-S vaccine.
Conclusions: The clinical significance of such coagulation homeostasis disruption remains to be elucidated but it is worthy of global scientific follow-up effort.
Keywords: COVID-19 vaccines; antithrombin; coagulation factors.
. 2022 Jul 31;10(8):1226.
doi: 10.3390/vaccines10081226.
Association of COVID-19 Vaccines ChAdOx1-S and BNT162b2 with Circulating Levels of Coagulation Factors and Antithrombin
Amal Hasan[SUP] 1 [/SUP], Hossein Arefanian[SUP] 1 [/SUP], Arshad Mohamed Channanath[SUP] 2 [/SUP], Irina AlKhairi[SUP] 3 [/SUP], Preethi Cherian[SUP] 3 [/SUP], Sriraman Devarajan[SUP] 4 [/SUP], Thangavel Alphonse Thanaraj[SUP] 2 [/SUP], Mohamed Abu-Farha[SUP] 4 [/SUP], Jehad Abubaker[SUP] 3 [/SUP], Fahd Al-Mulla[SUP] 2 [/SUP]
Affiliations
- PMID: 36016114
- DOI: 10.3390/vaccines10081226
Abstract
Background: Severe coronavirus disease 2019 (COVID-19) is associated with increased risk of thrombosis and thromboembolism. Exposure to COVID-19 vaccines is also associated with immune thrombotic thrombocytopenia, ischemic stroke, intracerebral haemorrhage, and cerebral venous thrombosis, and it is linked with systemic activation of coagulation.
Methods: We assess the circulating levels of coagulation factors (factors XI, XII, XIII, and prothrombin) and antithrombin in individuals who completed two doses of either ChAdOx1-S or BNT162b2 COVID-19 vaccine, within the timeframe of two months, who had no previous history of COVID-19.
Results: Elevated levels of factors XI, XII, XIII, prothrombin, and antithrombin were seen compared to unvaccinated controls. Levels of coagulation factors, antithrombin, and prothrombin to antithrombin ratio were higher with BNT162b2 compared to ChAdOx1-S vaccine.
Conclusions: The clinical significance of such coagulation homeostasis disruption remains to be elucidated but it is worthy of global scientific follow-up effort.
Keywords: COVID-19 vaccines; antithrombin; coagulation factors.